SCHEMBL4872810

SCHEMBL4872810

O=C1C(Nc2ccc(O)cc2)=C(N2CCCC2)C(=O)c2ccccc21

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 14/20 0.76
▸ APAF1 O14727 13/20 0.76
▸ ALDH1A1 P00352 9/20 0.76
▸ SMN1; SMN2 Q16637 6/20 0.76
▸ NPC1 O15118 6/20 0.76
▸ POLB P06746 6/20 0.76
▸ HTT P42858 5/20 0.76
▸ LMNA P02545 4/20 0.76
▸ MITF O75030 4/20 0.76
▸ KLF5 Q13887 1/20 0.76
▸ RAB9A P51151 6/20 0.73
▸ L3MBTL1 Q9Y468 6/20 0.72
▸ MEN1 O00255 5/20 0.72
▸ KMT2A Q03164 5/20 0.72
▸ NPSR1 Q6W5P4 4/20 0.72
▸ GAA P10253 4/20 0.72
▸ NSD2 O96028 2/20 0.72
▸ KDM4E B2RXH2 4/20 0.70
▸ TDP1 Q9NUW8 4/20 0.70
▸ RECQL P46063 2/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7247303 0.88 MAPT (0.97) MAPTAPAF1ALDH1A1SMN1; SMN2NPC1
SCHEMBL16297187 0.87 APAF1 (1.00) MAPTAPAF1ALDH1A1SMN1; SMN2NPC1
SCHEMBL7247910 0.86 APAF1 (0.76) MAPTAPAF1ALDH1A1SMN1; SMN2NPC1
SCHEMBL4874221 0.86 APAF1 (0.97) MAPTAPAF1ALDH1A1SMN1; SMN2NPC1
SCHEMBL16297041 0.86 MAPT (0.76) MAPTAPAF1ALDH1A1SMN1; SMN2NPC1
SCHEMBL7246128 0.86 MAPT (0.76) MAPTAPAF1ALDH1A1SMN1; SMN2NPC1
SCHEMBL16296946 0.84 MAPT (0.79) MAPTAPAF1ALDH1A1SMN1; SMN2NPC1
SCHEMBL5807881 0.84 APAF1 (1.00) MAPTAPAF1ALDH1A1SMN1; SMN2NPC1
SCHEMBL16296652 0.84 MAPT (0.79) MAPTAPAF1ALDH1A1SMN1; SMN2NPC1
SCHEMBL16296848 0.84 APAF1 (0.79) MAPTAPAF1ALDH1A1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9272993-B2 Naphthoquinone derivatives useful for prevention of amyloid deposits and treatment of diseases involving amyloidogenesis RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) 2016-03-01 — — US disclosed
US-9272993-B2 Naphthoquinone derivatives useful for prevention of amyloid deposits and treatment of diseases involving amyloidogenesis RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) 2016-03-01 — — US disclosed
US-20140213627-A1 NAPHTHOQUINONE DERIVATIVES USEFUL FOR PREVENTION OF AMYLOID DEPOSITS AND TREATMENT OF DISEASES INVOLVING AMYLOIDOGENESIS RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) 2014-07-31 — — US disclosed
US-20140213627-A1 NAPHTHOQUINONE DERIVATIVES USEFUL FOR PREVENTION OF AMYLOID DEPOSITS AND TREATMENT OF DISEASES INVOLVING AMYLOIDOGENESIS RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) 2014-07-31 — — US disclosed
US-8513437-B2 Pyrrolidino-1,4-naphthoquinone deriviatives and their use for treating malignancies and cardiovascular diseases BEN GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY (IS) 2013-08-20 — — US disclosed
US-20110224184-A1 NAPHTHOQUINONE DERIVATIVES USEFUL FOR PREVENTION OF AMYLOID DEPOSITS AND TREATMENT OF DISEASES INVOLVING AMYLOIDOGENESIS RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) 2011-09-15 — — US disclosed
US-20110224184-A1 NAPHTHOQUINONE DERIVATIVES USEFUL FOR PREVENTION OF AMYLOID DEPOSITS AND TREATMENT OF DISEASES INVOLVING AMYLOIDOGENESIS RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) 2011-09-15 — — US disclosed
WO-2010026592-A1 NAPHTHOQUINONE DERIVATIVES USEFUL FOR PREVENTION OF AMYLOID DEPOSITS AND TREATMENT OF DISEASES INVOLVING AMYLOIDOGENESIS RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) 2010-03-11 — — WO disclosed
US-20080300274-A1 Novel Pyrrolidino-1,4-Naphthoquinone Deriviatives and their Use for Treating Malignancies and Cardiovascular Diseases BEN GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY (IL) 2008-12-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140213627-A1 NAPHTHOQUINONE DERIVATIVES USEFUL FOR PREVENTION OF AMYLOID DEPOSITS AND TREATMENT OF DISEASES INVOLVING AMYLOIDOGENESIS APP, PSEN1, PSEN2 MAPT 14/4885APAF1 3286/4885ALDH1A1 2528/4885
US-20080300274-A1 Novel Pyrrolidino-1,4-Naphthoquinone Deriviatives and their Use for Treating Malignancies and Cardiovascular Diseases MAPK1, MAP3K1, MAP3K20 MAPT 3144/4885APAF1 1872/4885ALDH1A1 1803/4885
US-20110224184-A1 NAPHTHOQUINONE DERIVATIVES USEFUL FOR PREVENTION OF AMYLOID DEPOSITS AND TREATMENT OF DISEASES INVOLVING AMYLOIDOGENESIS APP, PSEN1, PSEN2 MAPT 14/4885APAF1 3286/4885ALDH1A1 2528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback